Accelerating the Pace of Protein Functional Annotation With Intel Xeon Phi Coprocessors

MCtandem: an efficient tool for large-scale peptide identification on many integrated core (MIC) architecture

Background

Tandem mass spectrometry (MS/MS)-based database searching is a widely acknowledged and widely used method for peptide identification in shotgun proteomics. However, due to the rapid growth of spectra data produced by advanced mass spectrometry and the greatly increased number of modified and digested peptides identified in recent years, the current methods for peptide database searching cannot rapidly and thoroughly process large MS/MS spectra datasets. A breakthrough in efficient database search algorithms is crucial for peptide identification in computational proteomics.

Results

This paper presents MCtandem, an efficient tool for large-scale peptide identification on Intel Many Integrated Core (MIC) architecture. To support big data processing capability, a novel parallel match scoring algorithm, named MIC-SDP (spectrum dot product), and its two-level parallelization are presented in MCtandem’s design. In addition, a series of optimization strategies on both the host CPU side and the MIC side, which includes pre-fetching, optimized communication overlapping scheme, multithreading and hyper-threading, are exploited to improve the execution performance.

Conclusions

For fair comparisons, we first set up experiments and verified the 28 fold times speedup on a single MIC against the original CPU-based implementation. We then execute the MCtandem for a very large dataset on an MIC cluster (a component of the Tianhe-2 supercomputer) and achieved much higher scalability than in a benchmark MapReduce-based programs, MR-Tandem. MCtandem is an open-source software tool implemented in C++. The source code and the parameter settings are available at https://github.com/LogicZY/MCtandem.

Local Alignment of Ligand Binding Sites in Proteins for Polypharmacology and Drug Repositioning

The administration of drugs is a key strategy in pharmacotherapy to treat diseases. Drugs are typically developed to modulate the function of specific proteins, which are directly associated with particular disease states. Nonetheless, recent studies suggest that protein-drug interactions are rather promiscuous and the majority of pharmaceuticals exhibit activity against multiple, often unrelated proteins. Certainly, the lack of selectivity often leads to drug side effects; on the other hand, these polypharmacological attributes can be used to develop drugs acting on multiple targets within a unique disease pathway, as well as to identify new targets for existing drugs, which is known as drug repositioning. To support drug development and repurposing, we developed eMatchSite, a new approach to detect those binding sites having the capability to bind similar compounds. eMatchSite is available as a standalone software and a webserver at http://www.brylinski.org/ematchsite .